Lung Injury and Repair
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 78250
Special Issue Editor
Interests: pathophysiology of acute lung injury and acute respiratory distress syndrome; P53 in the lung endothelium; unfolded protein response in the regulation of endothelial permeability; endoplasmic reticulum stress in the context of the lung microvasculature; heat shock proteins; extra hypothalamic effects of growth hormone-releasing hormone; endocrine-related cancer; reactive oxygen species; vascular biology
Special Issue Information
Dear Colleagues,
We are pleased to announce the launch of the “Lung Injury and Repair” Special Issue of Pharmaceuticals. This Special Issue will emphasize the most recent advances in the field of pulmonary biology and therapeutics, to provide the research and medical community with the most up-to-date information in the corresponding fields. We welcome the submission of manuscripts (research articles, reviews) investigating the etiologies of lung disease, as well as the development of medical countermeasures against lung injury (direct and indirect). Such injuries include (but are not limited to) the following: acute lung injury, acute respiratory distress syndrome, aspiration, sepsis, trauma, SARS-CoV-2-inflicted ARDS, pneumonia, fibrosis, lung endothelial, and epithelial cell injury. The further delineation of the signaling network that maintains states of lung health and disease will propel the discovery of highly targeted and efficacious approaches against the ferocious outcomes of respiratory dysfunction, including COVID-19.
Dr. Nektarios Barabutis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung injury
- acute respiratory distress syndrome
- COVID-19
- cardiovascular disease
- lung disease
- sepsis
- unfolded protein response
- endothelial permeability
- inflammation
- vascular biology